DEER PARK, Ill. , Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen , Chief Executive Officer, will present at the H.C.

Total Q2 revenue of $12.0 million and net income of $4.6 million Product sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2023 $21.6 million of cash on hand Launched Betaine Anhydrous Management to hold conference call today at 4:30pm ET DEER PARK, Ill. , Aug.

DEER PARK, Ill. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2023 financial results on Thursday, August

DEER PARK, Ill. , June 28, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response

Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022 Launched Betaine Anhydrous Management to hold conference call today at 4:30pm ET DEER PARK, Ill. , May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an

-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* -- -- Product is now available exclusively through Optime Care -- DEER PARK, Ill. , May 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company

DEER PARK, Ill. , May 03, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2023 financial results on Thursday, May 11,

Q4 2022 revenue of $8.5 million Q4 Product sales and royalty revenue up 220% from prior year and 9% from Q3 Q4 positive net income Management to hold conference call today at 4:30pm ET DEER PARK, Ill. , March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq:

-- Product is targeting rare pediatric endocrinology condition -- -- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill. , March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and

DEER PARK, Ill. , March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2022 financial results on Thursday, March